Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Amyloid-β and tau PET scans predict clinical progression in cognitively unimpaired people

Evidence — provided by a combination of amyloid-β and tau PET examinations — of advanced Alzheimer’s disease pathological changes in the brain in cognitively unimpaired individuals is strongly associated with short-term (3–5 years) cognitive decline. Thus, amyloid-β and tau PET have high clinical relevance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Clinical progression by amyloid-β and tau PET status.


  1. Jansen, W. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015). A meta-analysis showing that age and APOE genotype are the main risk factors for an abnormal amyloid-β PET scan.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1993). This paper reports a post-mortem staging system of neurofibrillary tau pathology, which increases with advancing age.

    Article  Google Scholar 

  3. Ossenkoppele, R. et al. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022). A Review article that discusses the current state of tau biomarkers and how they can improve clinical practice and trials.

    Article  CAS  PubMed  Google Scholar 

  4. Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–556 (2018). A consensus paper of a research framework proposing a biomarker-based definition of AD.

  5. Dubois, B. et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484–496 (2021). A consensus paper proposing that the term AD should be restricted to symptomatic individuals.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Hansson, O. et al. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. (2022).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amyloid-β and tau PET scans predict clinical progression in cognitively unimpaired people. Nat Med 28, 2267–2268 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing